CHENNAI: Lupin Ltd has announced its US subsidiary, Lupin Pharmaceuticals Inc., secured a nod for its ‘levonorgestrel and ethinyl estradiol’ tablets from the United States Food and Drug Administration (USFDA) to market a version of Watson Laboratories’ ‘Lutera’ tablets.
Lupin’s levonorgestrel and ethinyl estradiol tablets have the strength of 0.1 mg and 0.02 mg. These are combined oral contraceptives directed for the prevention of pregnancy in women who use oral contraceptives to avoid pregnancy.
As per statement issued by the company, ''Lupin will be marketing its generic product shortly.'' The Lutera tablets have annual sales of nearly $104 million.